Inglês

Subject ID, age, race, composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy, and sex of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.

5 Formulários  
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    3. Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    4. Subject ID, age, race, composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy, and sex of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    5. Sample ID, body site where sample was obtained, analyte type, primary or metastatic tumor, primary tumor location, tumor stage, tumor treatment, treatment post visit, histological type, sequence center, and body site category where sample was collected [bone or tissue] of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
pht005601
Descrição

pht005601

Alias
UMLS CUI [1,1]
C3846158
De-identified subject ID
Descrição

SUBJECT_ID

Tipo de dados

string

Alias
UMLS CUI [1,1]
C4684638
UMLS CUI [1,2]
C2348585
Age at study enrollment
Descrição

age

Tipo de dados

text

Unidades de medida
  • Years
Alias
UMLS CUI [1,1]
C0001779
UMLS CUI [1,2]
C0011008
UMLS CUI [1,3]
C1516879
Years
Race [White, American Indian or Alaska Native, Asian, Black or African American, NA=Not reported: Patient refused or not available]
Descrição

race

Tipo de dados

string

Alias
UMLS CUI [1,1]
C0034510
Composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy (12-14 weeks or earlier if progression is suspected). The progression is judged based on PSA levels, radiography estimate progression, and symptoms assessments.
Descrição

composite_progression

Tipo de dados

string

Alias
UMLS CUI [1,1]
C5418619
UMLS CUI [1,2]
C0242656
UMLS CUI [1,3]
C1442461
UMLS CUI [1,4]
C0231290
UMLS CUI [1,5]
C2607886
UMLS CUI [1,6]
C0392920
Sex
Descrição

sex

Tipo de dados

string

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [2,1]
C0079399
Voltar ao início da página

Similar models

Subject ID, age, race, composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy, and sex of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.

5 Formulários
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    3. Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    4. Subject ID, age, race, composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy, and sex of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    5. Sample ID, body site where sample was obtained, analyte type, primary or metastatic tumor, primary tumor location, tumor stage, tumor treatment, treatment post visit, histological type, sequence center, and body site category where sample was collected [bone or tissue] of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
pht005601
C3846158 (UMLS CUI [1,1])
SUBJECT_ID
Item
De-identified subject ID
string
C4684638 (UMLS CUI [1,1])
C2348585 (UMLS CUI [1,2])
age
Item
Age at study enrollment
text
C0001779 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
C1516879 (UMLS CUI [1,3])
Item
Race [White, American Indian or Alaska Native, Asian, Black or African American, NA=Not reported: Patient refused or not available]
string
C0034510 (UMLS CUI [1,1])
race
Code List
Race [White, American Indian or Alaska Native, Asian, Black or African American, NA=Not reported: Patient refused or not available]
CL Item
No description (NA)
Item
Composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy (12-14 weeks or earlier if progression is suspected). The progression is judged based on PSA levels, radiography estimate progression, and symptoms assessments.
string
C5418619 (UMLS CUI [1,1])
C0242656 (UMLS CUI [1,2])
C1442461 (UMLS CUI [1,3])
C0231290 (UMLS CUI [1,4])
C2607886 (UMLS CUI [1,5])
C0392920 (UMLS CUI [1,6])
composite_progression
Code List
Composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy (12-14 weeks or earlier if progression is suspected). The progression is judged based on PSA levels, radiography estimate progression, and symptoms assessments.
CL Item
Progressor (Yes)
CL Item
Non-progressor (No)
CL Item
Not available (N/A)
Item
Sex
string
C0079399 (UMLS CUI [1,1])
C0079399 (UMLS CUI [2,1])
sex
Code List
Sex
CL Item
Male (M)
C0086582 (UMLS CUI [1,1])
Voltar ao início da página